Galectin Therapeutics Inc (GALT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Galectin Therapeutics Inc (GALT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH81909D
  • |
  • Pages: 51
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Galectin Therapeutics Inc (Galectin Therapeutics), formerly Pro-Pharmaceuticals Inc is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GR-MD-02 and GM-CT-01. Its GR-MD-02 is a drug candidate used for treating fibrotic liver disease. Its GM-CT-01 is a vaccine used to treat patients with advanced melanoma, a deadly skin cancer. Galectin Therapeutics offers research and study of science of galectin proteins. The company's products are used to treat fibrosis, galectin effects on liver fibrosis, lung fibrosis and others. Galectin Therapeutics is headquartered in Norcross, Georgia, the US.

Galectin Therapeutics Inc (GALT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Galectin Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Galectin Forms Joint Venture With SBH Sciences 12

Galectin Therapeutics Enters Into Discovery Agreement With University of Georgia For Anti-Galectin Drugs 13

Galectin Therapeutics Enters Into Research Agreement With University of Michigan 14

Equity Offering 15

Galectin Therapeutics Plans to Raise up to USD30 Million in Public Offering of Shares 15

Galectin Therapeutics Raises USD3 Million in Private Placement of Shares 16

Galectin Therapeutics Announces Secondary Offering of Shares 17

Galectin Therapeutics Prices Private Placement of Shares for USD9.8 Million 18

Galectin Therapeutics Completes Public Offering Of Common Stock For USD24 Million 19

Galectin Therapeutics Completes Private Placement Of Shares For USD3 Million Upon Exercise Of Warrants 20

Galectin Therapeutics Completes Private Placement Of Shares For USD3 Million 21

Galectin Therapeutics Completes Public Offering Of Units For USD12 Million 22

PRO-Pharma Files Registration Statement For Public Offering Of USD50 Million 23

Pro-Pharma Completes Private Placement Of USD2.1 Million 24

Pro-Pharma Completes Second Tranche Of Private Placement Of USD1 Million 26

Galectin Therapeutics Inc-Key Competitors 27

Galectin Therapeutics Inc-Key Employees 28

Galectin Therapeutics Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Joint Venture 29

Recent Developments 30

Financial Announcements 30

Aug 14, 2017: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update 30

May 15, 2017: Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update 32

Mar 28, 2017: Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update 34

Nov 08, 2016: Galectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update 36

Aug 09, 2016: Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update 38

May 10, 2016: Galectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update 40

Mar 15, 2016: Galectin Therapeutics Reports 2015 Financial Results and Provides Business Update 41

Corporate Communications 43

Mar 23, 2017: Galectin Therapeutics Issues Statement Regarding GALTW and GALTU 43

Jan 08, 2016: Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors 44

Product News 45

01/07/2016: Galectin Therapeutics Posts "2015-2016, Progress and Possibilities" to Corporate Website 45

Clinical Trials 47

Jun 02, 2016: Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension 47

May 16, 2016: Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis 48

May 11, 2016: Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis 49

May 05, 2016: Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51

List of Figures

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Galectin Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Galectin Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Galectin Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10

Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Galectin Forms Joint Venture With SBH Sciences 12

Galectin Therapeutics Enters Into Discovery Agreement With University of Georgia For Anti-Galectin Drugs 13

Galectin Therapeutics Enters Into Research Agreement With University of Michigan 14

Galectin Therapeutics Plans to Raise up to USD30 Million in Public Offering of Shares 15

Galectin Therapeutics Raises USD3 Million in Private Placement of Shares 16

Galectin Therapeutics Announces Secondary Offering of Shares 17

Galectin Therapeutics Prices Private Placement of Shares for USD9.8 Million 18

Galectin Therapeutics Completes Public Offering Of Common Stock For USD24 Million 19

Galectin Therapeutics Completes Private Placement Of Shares For USD3 Million Upon Exercise Of Warrants 20

Galectin Therapeutics Completes Private Placement Of Shares For USD3 Million 21

Galectin Therapeutics Completes Public Offering Of Units For USD12 Million 22

PRO-Pharma Files Registration Statement For Public Offering Of USD50 Million 23

Pro-Pharma Completes Private Placement Of USD2.1 Million 24

Pro-Pharma Completes Second Tranche Of Private Placement Of USD1 Million 26

Galectin Therapeutics Inc, Key Competitors 27

Galectin Therapeutics Inc, Key Employees 28

Galectin Therapeutics Inc, Joint Venture 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Galectin Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16090
Site License
USD 500 INR 32180
Corporate User License
USD 750 INR 48270

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com